Skip to search formSkip to main contentSkip to account menu

AQ4N

Known as: 1,4-bis-((2-(dimethylamino-N-oxide)ethyl)amino)-5,8-dihydroxyanthracene-9,10-dione, 9,10-Anthracenedione, 1,4-bis((2-(dimethylamino)ethyl)amino)-5,8-dihydroxy-, N,N'-dioxide, BANOXANTRONE 
A bioreductive, alkylaminoanthraquinone prodrug with antineoplastic activity. Under hypoxic conditions, often seen in solid tumors, banoxantrone… 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Anthraquinones
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Cytochrome P450 2S1 is Reduced by NADPH-Cytochrome P450 Reductase
Cytochrome P450 (P450) 2S1 is one of the orphan P450s without a clear physiological function. Controversy has arisen as to… 
Highly Cited
2009
Highly Cited
2009
The hypoxia-activated ProDrug AQ4N penetrates deeply in tumor tissues and complements the limited distribution of mitoxantrone.
Hypoxic tumor cells are likely to be resistant to conventional chemotherapy, in large part because many anticancer drugs are… 
2008
2008
Evaluation of the Antiangiogenic Potential of AQ4N
Purpose: A number of cytotoxic chemotherapy agents tested at low concentrations show antiangiogenic properties with limited… 
Highly Cited
2007
Highly Cited
2007
Examination of the distribution of the bioreductive drug AQ4N and its active metabolite AQ4 in solid tumours by imaging matrix-assisted laser desorption/ionisation mass spectrometry.
AQ4N (banoxatrone) (1,4-bis-{[2-(dimethylamino-N-oxide)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione) is an example of a… 
2004
2004
The Azinomycins. Discovery, Synthesis, and DNA‐Binding Studies
Nature is a rich source of antitumour agents that can act as a paradigm for the development of synthetic agents that retain the… 
2001
2001
A preclinical pharmacokinetic study of the bioreductive drug AQ4N.
AQ4N (1,4-bis-[[2-(dimethylamino-N-oxide)ethyl]amino]5,8-dihydroxyanthracene-9,10-dione) is in a class of bioreductive agents… 
Highly Cited
2000
Highly Cited
2000
Hypoxia-dependent retinal toxicity of bioreductive anticancer prodrugs in mice.
The bioreductive anticancer prodrug CI-1010 ((2R)-1-[(2-bromoethyl)amino]-3-(2-nitro-1H-imidazol-1-yl)-2-propanol hydrobromide… 
1999
1999
Rat cytochromes P450 (CYP) specifically contribute to the reductive bioactivation of AQ4N, an alkylaminoanthraquinone-di-N-oxide anticancer prodrug.
1. The bioreductive activation of the alkylaminoanthraquinone di-N-oxide prodrug AQ4N has been characterized in rat hepatic… 
Highly Cited
1998
Highly Cited
1998
Involvement of human cytochromes P450 (CYP) in the reductive metabolism of AQ4N, a hypoxia activated anthraquinone di-N-oxide prodrug.
1996
1996
Evidence for a therapeutic gain when AQ4N or tirapazamine is combined with radiation.
The use of bioreductive drugs as an adjunct to radiotherapy in the treatment of cancer is presently being tested in several… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)